Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 398 results for "continuous renal replacement therapy"

Pharmacokinetics of meropenem in children receiving continuous...

Abstract Meropenem is frequently prescribed in critically ill children receiving continuous renal replacement therapy (CRRT). We previously used clinical trial simulations to evaluate dosing regimens of meropenem in this population and reported a ... Journal of Clinical Pharmacology, 4 weeks ago

Tedizolid Adsorption and Transmembrane Clearance during in vitro Continuous Renal Replacement Therapy

General Please address all your queries or problem reports to the Pay-per-View Customer Service at ppv@karger.com referring to PPV or PPV account. 1. All payments are by credit card only. The transaction is secure: standard-procedure SSL or ...
 Blood Purification2 months ago

Improved Structure and Function in Autosomal Recessive Polycystic Rat Kidneys with Renal Tubular Cell Therapy

Abstract Autosomal recessive polycystic kidney disease is a truly catastrophic monogenetic disease, causing death and end stage renal disease in neonates and children. Using PCK female rats, an orthologous model of autosomal recessive polycystic ...
 Plosone.org1 month ago
India Today

Cardiac Breakthroughs

Heart disease continues to be the leading cause of illness and death in India and indeed across the world. But researchers are labouring on many fronts to find new ways to understand and treat this serious disease. What has changed: from lab bench ...
 Yahoo! India3 weeks ago

Barcelona continues to grow at speed

Barcelona is a smart city that both embraces and pioneers change. Provided to China Daily City combines innovation, investment and sustainability to stay ahead of the crowd Things just keep getting better in the vibrant city of Barcelona, the ...
 CHINAdaily.com.cn1 month ago
TheStreet.com

CheckMate -025, a Pivotal Phase III Opdivo (nivolumab) Renal Cell Cancer Trial, Stopped Early

PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol-Myers Squibb Company (NYSE:BMY) today announced that an open-label, randomized Phase III study evaluating Opdivo (nivolumab) versus everolimus in previously-treated patients with ...
 Business Wire1 month ago BRISTOL MYERS SQUIBB : CheckMate -025, a Pivotal Phase III Opdivo (nivolumab) Renal Cell Cancer Trial, Stopped Early  4 Traders1 month ago Bristol-Myers Squibb Release: European Commission (EC) Approves Nivolumab BMS, The First PD-1 Immune Checkpoint Inhibitor In Europe Proven To Extend Survival For Patients With Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer  BioSpace1 month ago Bristol Myers Squibb : European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer  4 Traders1 month ago
[x]  

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

In systemic amyloidosis, the extracellular deposition of normally soluble plasma proteins as insoluble amyloid fibrils damages the structure and function of tissues and organs. 1 Current treatment consists of support or replacement of failing organs ...
 New England Journal of Medicine1 month ago
Benzinga.com

NxStage System One Now in Eight of Top 10 U.S. Nephrology Hospitals

LAWRENCE, Mass. The System One offers multiple features designed to simplify therapies in hospitals. These features include the NxView interface with graphical touch screen display that provides treatment information and charting assistance, a ...
 Benzinga.com2 weeks ago NxStage Medical, Inc. (NXTM) System One Now In Eight Of Top 10 U.S. Nephrology Hospitals 8/12/2015  ClinicSpace2 weeks ago NxStage Medical, Inc. System One Now In Eight Of Top 10 U.S. Nephrology Hospitals  BioSpace2 weeks ago
[x]  

Rockwell Medical Schedules Second Quarter Earnings Call

(GLOBE NEWSWIRE) -- Rockwell Medical, Inc. ( RMTI ), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, ...
 Yahoo! Finance1 month ago Rockwell Medical Announces Triferic(TM) Phase 3 CRUISE Studies Published in Nephrology Dialysis Transplantation  Individual.com1 month ago ROCKWELL MEDICAL : Schedules Second Quarter Earnings Call  4 Traders1 month ago ROCKWELL MEDICAL : Announces Triferic(TM) Phase 3 CRUISE Studies Published in Nephrology Dialysis Transplantation  4 Traders1 month ago
[x]  

Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa ® (vandetanib) from AstraZeneca

Company Website: http://www.genzyme.com CAMBRIDGE, Mass. -- (Business Wire) Genzyme, a Sanofi company, today announced that it has entered into a definitive agreement with AstraZeneca to acquire Caprelsa® (vandetanib), a rare disease therapy, ...
 Stockwatch1 month ago Sanofi: Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZeneca  Biotechgate1 month ago REG-Sanofi: Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa(R) (vandetanib) from AstraZeneca  Reuters1 month ago SANOFI : Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZeneca  4 Traders1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less